Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 21.84
+0.17 (0.78%)
Jan 23, 2026, 10:09 AM CST
Nanjing Vazyme Biotech Revenue
Nanjing Vazyme Biotech had revenue of 346.18M CNY in the quarter ending September 30, 2025, with 2.84% growth. This brings the company's revenue in the last twelve months to 1.34B, down -4.15% year-over-year. In the year 2024, Nanjing Vazyme Biotech had annual revenue of 1.38B with 7.15% growth.
Revenue (ttm)
1.34B
Revenue Growth
-4.15%
P/S Ratio
6.41
Revenue / Employee
468.92K
Employees
2,754
Market Cap
8.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.38B | 91.91M | 7.15% |
| Dec 31, 2023 | 1.29B | -2.28B | -63.97% |
| Dec 31, 2022 | 3.57B | 1.70B | 90.99% |
| Dec 31, 2021 | 1.87B | 304.17M | 19.44% |
| Dec 31, 2020 | 1.56B | 1.30B | 482.92% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi AppTec | 43.88B |
| Huadong Medicine | 43.09B |
| Yunnan Baiyao Group Co.,Ltd | 40.77B |
| Shanghai Fosun Pharmaceutical (Group) | 39.55B |
| Shenzhen Mindray Bio-Medical Electronics | 33.07B |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 30.98B |
| Zhejiang NHU Company | 22.47B |
| Aier Eye Hospital Group | 22.17B |